A Bitcoin address that had held coins since 2013 made its first recorded transaction on October 18, moving 411.45 BTC valued at about $33.4 million to a new address. The coins were originally received in separate transactions in 2013 and had remained untouched for nearly a decade. The receiving address has shown no further outgoing transactions, so it is unclear if the Bitcoin was sold or simply transferred. This move highlights activity from a long-dormant wallet, which could attract attention from investors and analysts monitoring large Bitcoin movements.
The recent movement of 411.45 BTC from a dormant Bitcoin address provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, as of Oct 20, 2026 00:31 WIB, 40 out of 50 major cryptocurrencies rose while 9 fell. Notable price changes include EOS up 8.13% at Rp12.649 and DOT up 7.43% at Rp20.751 with a typical hold time of 121 days and a Pluang order activity of 83% Sell / 17% Buy.
Ethereum-based crypto Pepeto is in its final presale stages ahead of a Binance listing, with rapid investor interest driving record presale speed. Pepeto addresses issues Cardano aimed to fix, such as high fees and network congestion, offering zero-f...
Miracles, a company specializing in personalized children's books where each child becomes the story's hero, has printed over 100,000 books for more than 45,000 families. The books are printed locally in Germany and delivered within a few days, offer...
Miracles, a personalized children's book maker, has printed more than 100,000 books, serving over 45,000 families. Each book features a unique 3D character of the child, created from a single photo, making the child the hero of the story. Books for U...
The global migraine market is projected to expand at a 6% annual growth rate through 2036, driven by rising migraine prevalence, better diagnosis, and awareness. Innovative treatments beyond traditional CGRP inhibitors, including PACAP-targeted thera...
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
